Kim Midwood
BSc (Hons), PhD
Professor of Matrix Biology
Professor Kim Midwood graduated with a B.Sc. (HONS) in Biochemistry from Edinburgh University in 1995. She completed her Ph.D. in the Department of Pathology at Edinburgh University in 1999, focusing on how changes in the extracellular matrix affect cellular signalling pathways in arthritis. She undertook postdoctoral training in the lab of Professor Jean Schwarzbauer, at Princeton University from 1999, continuing her work investigating the molecular mechanisms by which the cellular environment defines cell phenotype.
In 2004 she established the Matrix Immunology group in the Kennedy Institute of Rheumatology at Imperial College London, moving to Oxford University in 2011.
In 2007 she won an MRC New Investigators Award and in 2012 an Arthritis Research UK Senior Fellowship.
She founded the BioTech company Nascient Ltd in 2012.
Key publications
-
Location, location, location: how the tissue microenvironment affects inflammation in RA.
Journal article
Buckley CD. et al, (2021), Nat rev rheumatol, 17, 195 - 212
-
Matrix-Targeting Immunotherapy Controls Tumor Growth and Spread by Switching Macrophage Phenotype.
Journal article
Deligne C. et al, (2020), Cancer immunol res, 8, 368 - 382
-
Mapping tenascin-C interaction with toll-like receptor 4 reveals a new subset of endogenous inflammatory triggers.
Journal article
Zuliani-Alvarez L. et al, (2017), Nat commun, 8
-
Identification of an immunodominant peptide from citrullinated tenascin-C as a major target for autoantibodies in rheumatoid arthritis.
Journal article
Schwenzer A. et al, (2016), Ann rheum dis, 75, 1876 - 1883
-
Distinct microenvironmental cues stimulate divergent TLR4-mediated signaling pathways in macrophages.
Journal article
Piccinini AM. et al, (2016), Sci signal, 9
-
Startups on the menu.
Journal article
Midwood K., (2013), Nat biotechnol, 31
Recent publications
-
Tracing the origins of lung fibrosis.
Journal article
Buckley CD. and Midwood KS., (2024), Nat immunol
-
Extracellular matrix complexity in Q1
biomarker studies: a novel assay Q2
detecting total serum tenascin-C
reveals different distribution to
isoform-specific assays
Journal article
MIDWOOD KIM., (2023), Frontiers in immunology
-
Chemokine Binding to Tenascin-C Influences Chemokine-Induced Immune Cell Migration.
Journal article
Domaingo A. et al, (2023), Int j mol sci, 24
-
Investigating Chemokine-Matrix Networks in Breast Cancer: Tenascin-C Sets the Tone for CCL2.
Journal article
Gschwandtner M. et al, (2023), Int j mol sci, 24
-
Tenascin-C is a driver of inflammation in the DSS model of colitis
Journal article
MIDWOOD KIM., (2022), Matrix biology plus